Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Alterations of Neuromuscular Environment Are Associated with Chronic Tissue Hypoxia in β-Thalassemia Patients

Andrea Piolatto, Gennaro Boccia, Alessandra Manca, Carmen Gaglioti, Teresa Ceglie, Caterina Cosentino, Luca Beratto, Jessica Cusato, Patrizia Falco, Silvia De Carlo, Filomena Longo, Antonella Roetto, Antonio Piga, Antonio D'Avolio, Alberto Rainoldi, Giovanni Battista Ferrero

Blood (2022) 140 (Supplement 1): 8208–8209.

https://doi.org/10.1182/blood-2022-168830

Published: 2022

Journal Articles

Prognostic Value of Serum Ferritin, Transferrin Saturation and C- Reactive Protein At Diagnosis In Myelodysplastic Syndrome Patients: Analysis of Patients From the MDS Piedmont Registry,

Emanuela Messa, Daniela Gioia, Claudia Bertassello, Gianni Ciccone, Andrea Evangelista, Ceccarelli Manuela, Bernardino Allione, Daniela Cilloni, MD, PhD, Flavia Salvi, MD, Gianni Cametti, Monia Lunghi, Dario Ferrero, Patrizia Falco, Margherita Bonferroni, Giuseppe Saglio, MD, Alessandro Levis, MD

Blood (2011) 118 (21): 3807.

https://doi.org/10.1182/blood.V118.21.3807.3807

Published: 2011

Journal Articles

A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients

Antonio Palumbo, Patrizia Falco, Giulia Benevolo, Davide Rossi, Angelo Michele Carella, Tommasina Guglielmelli, Alberto Rocci, Lorenzo De Paoli, Mariella Grasso, Maria Letizia Mosca Siez, Eugenio Piro, Simona Caltagirone, Francesca Gay, Federica Cavallo, Gianluca Gaidano, Mario Boccadoro

Blood (2010) 116 (21): 1940.

https://doi.org/10.1182/blood.V116.21.1940.1940

Published: 2010

Journal Articles

Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.

Francesca Gay, MD, Patrizia Falco, MD, Claudia Crippa, MD, Anna Marina Liberati, MD, Francesca Patriarca, MD, Clotilde Cangialosi, MD, Vincenzo Capparella, MD, Agostina Siniscalchi, MD, Manuela Rizzo, MD, Luca De Rosa, MD, Antonietta Pia Falcone, MD, Simona Caltagirone, PhD, Sara Bringhen, MD, Paolo Corradini, MD, Mario Boccadoro, MD, Antonio Palumbo, MD

Blood (2009) 114 (22): 3419.

https://doi.org/10.1182/blood.V114.22.3419.3419

Published: 2009

Journal Articles

Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.

Blood (2009) 114 (22): 2877.

https://doi.org/10.1182/blood.V114.22.2877.2877

Published: 2009

Journal Articles

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Antonio Palumbo, MD, Patrizia Falco, MD, Francesca Gay, MD, Paolo Corradini, MD, Claudia Crippa, MD, Francesco Di Raimondo, MD, Antonietta Falcone, MD, Nicola Giuliani, MD, Pellegrino Musto, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Simona Caltagirone, PhD, Jerome B. Zeldis, MD, Robert D. Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2008) 112 (11): 2768.

https://doi.org/10.1182/blood.V112.11.2768.2768

Published: 2008

Journal Articles

Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study

Maria Teresa Petrucci, Elisabetta Calabrese, Anna Levi, Vincenzo Federico, Michela Ceccolini, Rita Rizzi, Alessandro Gozzetti, Patrizia Falco, Maria Caterina Cavallo, Simone Gerzelli, Mario Boccadoro, Francesco Lauria, Vincenzo Liso, Michele Cavo, Robert Foa

Blood (2008) 112 (11): 2393.

https://doi.org/10.1182/blood.V112.11.2393.2393

Published: 2008

Journal Articles

Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients

Antonio Palumbo, MD, Patrizia Falco, MD, Francesca Gay, MD, Vittorio Montefusco, MD, Claudia Crippa, MD, Francesca Patriarca, MD, Milena Gilestro, PhD, Anna M. Liberati, MD, Fausto Rossini, MD, Tommaso Caravita, MD, Antonietta Falcone, MD, Federica Cavallo, MD, Paolo Corradini, MD, Giuseppe Rossi, MD, Mario Boccadoro, MD

Blood (2008) 112 (11): 159.

https://doi.org/10.1182/blood.V112.11.159.159

Published: 2008

Journal Articles

Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial

Antonio Palumbo, MD, Patrizia Falco, MD, Grazia Sanpaolo, MD, Antonietta Falcone, MD, Vincenzo Ferderico, MD, Letizia Canepa, MD, Monica Crugnola, MD, Luca Baldini, MD, Alessandra Larocca, MD, Valeria Magarotto, MD, Maria Teresa Petrucci, MD, Mario Boccadoro, MD

Blood (2008) 112 (11): 868.

https://doi.org/10.1182/blood.V112.11.868.868

Published: 2008

Journal Articles

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Blood (2008) 112 (8): 3107–3114.

https://doi.org/10.1182/blood-2008-04-149427

Published: 2008

Journal Articles

Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m 2 in Elderly Newly Diagnosed Patients: An Interim Analysis.

Antonio Palumbo, MD, Ilaria Avonto, MD, Francesca Patriarca, MD, Claudia Crippa, MD, Maria T. Petrucci, MD, Fausto Rossini, MD, Paolo Corradini, MD, Anna M. Liberati, MD, Nicola Giuliani, MD, Norbert Pescosta, MD, Patrizia Falco, MD, Alessandra Larocca, MD, Paola Omedè, MD, Massimo Offidani, MD, Renato Fanin, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 448.

https://doi.org/10.1182/blood.V110.11.448.448

Published: 2007

Journal Articles

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Antonio Palumbo, MD, Alessandra Larocca, MD, Cecilia Rus, MD, Francesca Gay, MD, Davide Rossi, MD, Patrizia Pregno, MD, Patrizia Falco, MD, Ilaria Avonto, MD, Valeria Magarotto, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 2715.

https://doi.org/10.1182/blood.V110.11.2715.2715

Published: 2007

Journal Articles

Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience.

Tommaso Caravita, MD, Maria Teresa Petrucci, MD, Alessandra Spagnoli, Agostina Siniscalchi, MD, Massimo Offidani, MD, Vincenzo Federico, MD, Patrizia Falco, MD, Manuela Rizzo, MD, Antonio Palumbo, MD, Paolo de Fabritiis, MD

Blood (2007) 110 (11): 4823.

https://doi.org/10.1182/blood.V110.11.4823.4823

Published: 2007

Journal Articles

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, Patrizia Pregno, Norbert Pescosta, Vincenzo Callea, Clotilde Cangialosi, Tommaso Caravita, Fortunato Morabito, Pellegrino Musto, Sara Bringhen, Patrizia Falco, Ilaria Avonto, Federica Cavallo, Mario Boccadoro, for the Italian Multiple Myeloma Network, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA)

Blood (2006) 109 (7): 2767–2772.

https://doi.org/10.1182/blood-2006-08-042275

Published: 2006

Journal Articles

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (MEL200) Versus Melphalan 100 mg/m 2 (MEL100) in Newly Diagnosed Myeloma Patients.

Antonio Palumbo, MD, Sara Bringhen, MD, Maria Teresa Petrucci, MD, Antonietta Falcone, MD, Anna Marina Liberati, MD, Mariella Grasso, MD, Francesco Pisani, MD, Tommaso Caravita, MD, Patrizia Pregno, MD, Andrea Nozza, MD, Paola Omedè, MD, Patrizia Falco, MD, Pellegrino Musto, MD, Robin Foà, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 55.

https://doi.org/10.1182/blood.V108.11.55.55

Published: 2006

Journal Articles

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Antonio Palumbo, MD, Sara Bringhen, MD, Patrizia Falco, MD, Cecilia Rus, MD, Federica Cavallo, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Gabriele Gallone, MD, Tommaso Caravita, MD, Benedetto Bruno, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3562.

https://doi.org/10.1182/blood.V108.11.3562.3562

Published: 2006

Journal Articles

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Antonio Palumbo, MD, Patrizia Falco, MD, Antonietta Falcone, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Nicola Giuliani, MD, Giuseppe Rossi, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Maria Teresa Ambrosini, MD, Jerome Zeldis, MD, Robert Knight, MD, Robin Foà, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2006) 108 (11): 800.

https://doi.org/10.1182/blood.V108.11.800.800

Published: 2006

Journal Articles

Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.

Antonio Palumbo, MD, Maria Teresa Ambrosini, MD, Patrizia Pregno, MD, Norbert Pescosta, MD, Vincenzo Callea, MD, Clotilde Cangialosi, MD, Tommaso Caravita, MD, Fortunato Morabito, MD, Paola Omedè, PhD, Francesca Gay, MD, Ilaria Avonto, MD, Patrizia Falco, MD, Sara Bringhen, MD, Mario Boccadoro, MD

Blood (2005) 106 (11): 2553.

https://doi.org/10.1182/blood.V106.11.2553.2553

Published: 2005

Journal Articles

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Antonio Palumbo, MD, Patrizia Falco, MD, Pellegrino Musto, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Giuseppe Rossi, MD, Nicola Giuliani, MD, Fortunato Morabito, MD, Annalisa Luraschi, MD, Antonietta Falcone, MD, Paola Omedè, PhD, Francesca Gay, MD, Ilaria Avonto, MD, Maria Teresa Ambrosini, MD, Sara Bringhen, MD, Jerome Zeldis, MD, Robert Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2005) 106 (11): 785.

https://doi.org/10.1182/blood.V106.11.785.785

Published: 2005

Journal Articles

Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.

Blood (2005) 106 (11): 779.

https://doi.org/10.1182/blood.V106.11.779.779

Published: 2005

NARROW

Alterations of Neuromuscular Environment Are Associated with Chronic Tissue Hypoxia in β-Thalassemia Patients

Prognostic Value of Serum Ferritin, Transferrin Saturation and C- Reactive Protein At Diagnosis In Myelodysplastic Syndrome Patients: Analysis of Patients From the MDS Piedmont Registry,

A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients

Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.

Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study

Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients

Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m 2 in Elderly Newly Diagnosed Patients: An Interim Analysis.

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience.

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (MEL200) Versus Melphalan 100 mg/m 2 (MEL100) in Newly Diagnosed Myeloma Patients.

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only